Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 15 October 2025 - 18 October 2025

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences shares rose to $123 on October 17, 2025, up nearly 40% from a year ago, lifting its market value to about $150 billion. The company settled U.S. patent litigation over HIV drug Biktarvy, blocking generics until 2036. Its new HIV prevention shot Yeztugo is seeing strong uptake, and Moody’s raised Gilead’s outlook to “Positive.” Gilead also announced a $1.5 billion cell therapy deal with Pregene.
17 October 2025
··
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences said the FDA canceled a key meeting and imposed new trial demands for its lead drug zetomipzomib, delaying development by about two years. The company is now exploring a sale or merger and cutting costs. Shares jumped nearly 40% to $6 on Oct. 17. Kezar reported $90.2 million in cash as of Sept. 30 but faces higher expenses and extended a poison pill plan to 2026.
17 October 2025
··
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys Inc. shares surged 46% intraday on Oct. 16, 2025, closing up 35% at $0.745 amid heavy trading. The rally followed news of regulatory approvals for its FemBloc® birth control system in Europe, UK, and New Zealand, and a major order from a Spanish distributor. The company also announced new partnerships and showcased its fertility treatments at an industry conference. Femasys remains unprofitable but reported 85% year-over-year sales growth in Q2.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna shares rose 5% to $28 but remain down 35% in 2024 and nearly 80% below last year’s level. COVID vaccine sales have collapsed from $18.9 billion in 2022 to $3.1 billion, and Q2 revenue fell 41% to $142 million. The company cut its 2025 revenue forecast and is laying off 10% of staff. Early data from an experimental cancer vaccine showed a 24% tumor response rate in advanced melanoma.
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock a potential “100-bagger” on X, triggering volatility halts. The rally followed early trial results showing transplanted pancreatic cells produced insulin without immunosuppressive drugs. Sana raised $105 million in summer 2025, extending its cash runway into late 2026. Analyst ratings remain mixed, with targets ranging from $5 to $12.
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock “the next 100-bagger” on social media. Trading was briefly halted during the surge. The company recently reported positive diabetes cell-therapy trial data and raised $105 million, extending its cash runway into late 2026. Analyst price targets range from $5 to $12, with a consensus near $7.50.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion Pharmaceuticals’ stock jumped about 16% to $6.08 on Oct. 8, 2025, after renewed interest in its AI-driven drug discovery platform. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, ending the quarter with $534 million in cash. Management cut 20% of staff in mid-2025 to reduce costs. Analyst targets average $6.50, with mixed ratings.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech (NASDAQ: SEED) surged 92% in after-hours trading on Oct. 14, then fell back near $1.43 by Oct. 15. The Beijing agri-tech firm re-entered Northeast China, showcased new hybrid corn seeds, and announced a partnership with Fengtian Seed Industry. CEO Weibin Yan invested $2.4 million in September, with institutions adding $1.48 million. The stock spike followed U.S.-China trade tensions that lifted agriculture shares.
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion shares jumped 25% on Oct 14, closing at $7.84, after Merck exercised its option on the EVX-B3 vaccine, paying $7.5 million upfront with up to $592 million in milestones. Evaxion will present two-year Phase 2 data for its AI-designed melanoma vaccine at ESMO on Oct 17. The company also announced an upgrade to its AI-Immunology platform and maintains a “Strong Buy” rating from analysts.
15 October 2025
···
1 … 12 13 14 15 16

Stock Market Today

  • Wix.com (WIX) Faces Steep Share Price Decline, Valuation Close to Fair Value
    April 8, 2026, 6:30 PM EDT. Wix.com (WIX) stock has fallen sharply over multiple time frames, down 54.9% in one year and 74.3% in five years, reflecting significant market pressure. The stock recently closed at $74.40, showing a 17.8% drop in the past week. Despite this drop, a Discounted Cash Flow (DCF) model estimates Wix.com's intrinsic value at $69.88 per share, suggesting the current price trades about 6.5% above fair value. This implies investors may have factored in recent challenges, even as the company maintains positive cash flow projections. Wix.com's high price-to-earnings (P/E) ratio of 85.67 indicates strong growth expectations but also elevated risk. Investors should monitor valuation shifts amid ongoing volatility and changing market sentiment.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop